These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 20442857)
41. Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population. Zhang SY; Shibata H; Karino K; Wang BY; Kobayashi S; Masuda J; Nabika T Hypertens Res; 2007 May; 30(5):403-9. PubMed ID: 17587752 [TBL] [Abstract][Full Text] [Related]
42. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. Yeo A; Li L; Warren L; Aponte J; Fraser D; King K; Johansson K; Barnes A; MacPhee C; Davies R; Chissoe S; Tarka E; O'Donoghue ML; White HD; Wallentin L; Waterworth D PLoS One; 2017; 12(7):e0182115. PubMed ID: 28753643 [TBL] [Abstract][Full Text] [Related]
43. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy. Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS Prev Cardiol; 2010; 13(3):130-4. PubMed ID: 20626668 [TBL] [Abstract][Full Text] [Related]
44. Effects of dietary factors on lipoprotein-associated phospholipase A(2) (Lp-PLA (2)). Wong CK; White HD Curr Atheroscler Rep; 2011 Dec; 13(6):461-6. PubMed ID: 21870060 [TBL] [Abstract][Full Text] [Related]
45. Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome. Chae JS; Kim OY; Paik JK; Kang R; Seo WJ; Jeong TS; Sweeney G; Lee SH; Lee JH Atherosclerosis; 2011 Oct; 218(2):499-506. PubMed ID: 21762913 [TBL] [Abstract][Full Text] [Related]
46. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Corson MA; Jones PH; Davidson MH Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871 [TBL] [Abstract][Full Text] [Related]
49. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Gazi I; Lourida ES; Filippatos T; Tsimihodimos V; Elisaf M; Tselepis AD Clin Chem; 2005 Dec; 51(12):2264-73. PubMed ID: 16223884 [TBL] [Abstract][Full Text] [Related]
50. The role of lipoprotein-associated phospholipase A2 (Lp-PLA₂) in cardiovascular disease. Ikonomidis I; Michalakeas CA; Lekakis J; Parissis J; Anastasiou-Nana M Rev Recent Clin Trials; 2011 May; 6(2):108-13. PubMed ID: 21241231 [TBL] [Abstract][Full Text] [Related]
51. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Suzuki T; Solomon C; Jenny NS; Tracy R; Nelson JJ; Psaty BM; Furberg C; Cushman M Circ Heart Fail; 2009 Sep; 2(5):429-36. PubMed ID: 19808373 [TBL] [Abstract][Full Text] [Related]
52. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂. Rizos CV; Liberopoulos EN; Tellis CC; Florentin M; Elisaf MS; Tselepis AD Metab Syndr Relat Disord; 2011 Jun; 9(3):217-23. PubMed ID: 21352079 [TBL] [Abstract][Full Text] [Related]
53. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. Davis B; Koster G; Douet LJ; Scigelova M; Woffendin G; Ward JM; Smith A; Humphries J; Burnand KG; Macphee CH; Postle AD J Biol Chem; 2008 Mar; 283(10):6428-37. PubMed ID: 18165686 [TBL] [Abstract][Full Text] [Related]
54. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Jenny NS; Solomon C; Cushman M; Tracy RP; Nelson JJ; Psaty BM; Furberg CD Atherosclerosis; 2010 Apr; 209(2):528-32. PubMed ID: 19804884 [TBL] [Abstract][Full Text] [Related]
56. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. Rallidis LS; Tellis CC; Lekakis J; Rizos I; Varounis C; Charalampopoulos A; Zolindaki M; Dagres N; Anastasiou-Nana M; Tselepis AD J Am Coll Cardiol; 2012 Nov; 60(20):2053-60. PubMed ID: 23083783 [TBL] [Abstract][Full Text] [Related]
57. Genome-Wide Association Study Highlights Hoekstra M; Chen HY; Rong J; Dufresne L; Yao J; Guo X; Tsai MY; Tsimikas S; Post WS; Vasan RS; Rotter JI; Larson MG; Thanassoulis G; Engert JC Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):458-464. PubMed ID: 33115273 [TBL] [Abstract][Full Text] [Related]
58. Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke. Atik B; Johnston SC; Dean D PLoS One; 2010 Jun; 5(6):e11026. PubMed ID: 20543948 [TBL] [Abstract][Full Text] [Related]
59. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk? Lee JH; Engler MM Prog Cardiovasc Nurs; 2009 Dec; 24(4):181-9. PubMed ID: 20002343 [TBL] [Abstract][Full Text] [Related]
60. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Madjid M; Ali M; Willerson JT Tex Heart Inst J; 2010; 37(1):25-39. PubMed ID: 20200624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]